Importance:
Persistent symptoms after SARS-CoV-2 infection are an emerging public health problem. The duration of these symptoms remains poorly documented.
Objective:
To describe the temporal dynamics of persistent symptoms after SARS-CoV-2 infection and the factors associated with their resolution.
Design, Setting, And Participants:
This cross-sectional study involved 53 047 participants from 3 French adult population-based cohorts (CONSTANCES [Consultants des Centres d'Examens de Santé], E3N/E4N, and Nutrinet-Santé) who were included in a nationwide survey about SARS-CoV-2 infection. All participants were asked to complete self-administered questionnaires between April 1 and June 30, 2020. Variables included sociodemographic characteristics, comorbid conditions, COVID-19 diagnosis, and acute symptoms. Blood samples were obtained for serologic analysis between May 1 and November 30, 2020, from patients with SARS-CoV-2 infection defined as enzyme-linked immunosorbent assay immunoglobulin G antispike detection confirmed with a neutralization assay. A follow-up internet questionnaire was completed between June 1 and September 30, 2021, with details on persistent symptoms, their duration, and SARS-CoV-2 infection diagnosis by polymerase chain reaction.
Main Outcomes And Measures:
Persistent symptoms were defined as symptoms occurring during the acute infection and lasting 2 or more months. Survival models for interval-censored data were used to estimate symptom duration from the acute episode. Multivariable adjusted hazard ratios (HRs) were estimated for age, sex, and comorbid conditions. Factors associated with the resolution of symptoms were assessed.
Results:
A total of 3972 participants (2531 women [63.7%; 95% CI, 62.2%-65.2%]; mean [SD] age, 50.9 [12.7] years) had been infected with SARS-CoV-2. Of these 3972 participants, 2647 (66.6% [95% CI, 65.1%-68.1%]) reported at least 1 symptom during the acute phase. Of these 2647 participants, 861 (32.5% [95% CI, 30.8%-34.3%]) reported at least 1 persistent symptom lasting 2 or more months after the acute phase. After 1 year of follow-up, the estimated proportion of individuals with complete symptom resolution was 89.9% (95% CI, 88.7%-90.9%) with acute symptoms. Older age (>60 years; HR, 0.78; 95% CI, 0.68-0.90), female sex (HR, 0.64; 95% CI, 0.58-0.70), history of cancer (HR, 0.61; 95% CI, 0.47-0.79), history of tobacco consumption (HR, 0.80; 95% CI, 0.73-0.88), high body mass index (≥30: HR, 0.75; 95% CI, 0.63-0.89), and high number of symptoms during the acute phase (>4; HR, 0.43; 95% CI, 0.39-0.48) were associated with a slower resolution of symptoms.
Conclusions And Relevance:
In this cross-sectional study, persistent symptoms were still present in 10.1% of infected individuals at 1 year after SARS-CoV-2 infection. Given the high level of cumulative incidence of COVID-19, the absolute prevalent number of people with persistent symptoms is a public health concern.
Citing Articles
Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis.
Xu H, Lu T, Liu Y, Yang J, Ren S, Han B
Front Oncol. 2025; 14:1506366.
PMID: 39882453
PMC: 11774732.
DOI: 10.3389/fonc.2024.1506366.
Factors influencing the course of post-COVID-19-related symptoms: A bidirectional cohort study among employees in health and welfare services in Germany.
Steinke L, Peters C, Nienhaus A, Bethge M, Koch P
GMS Hyg Infect Control. 2024; 19:Doc61.
PMID: 39677013
PMC: 11638722.
DOI: 10.3205/dgkh000516.
Vitamin D deficiency and duration of COVID-19 symptoms in UK healthcare workers.
Chadda K, Roberts S, Lugg S, Faniyi A, Faustini S, Webster C
Front Med (Lausanne). 2024; 11:1494129.
PMID: 39655234
PMC: 11625565.
DOI: 10.3389/fmed.2024.1494129.
Factors associated with the development, severity, and resolution of post COVID-19 condition in adults living in Canada, January 2020 to August 2022.
Zakaria D, Demers A, Cheta N, Aziz S, Abdullah P
Can J Public Health. 2024; .
PMID: 39485635
DOI: 10.17269/s41997-024-00958-7.
How Long Is Long COVID? Evaluation of Long-Term Health Status in Individuals Discharged from a Specialist Community Long COVID Service.
Bodey R, Grimaldi J, Tait H, Godfrey B, Witton S, Shardha J
J Clin Med. 2024; 13(19).
PMID: 39407877
PMC: 11477015.
DOI: 10.3390/jcm13195817.
SARS-CoV-2 infection and the risk of depressive symptoms: a retrospective longitudinal study from the population-based CONSTANCES cohort.
Pignon B, Wiernik E, Ranque B, Robineau O, Carrat F, Severi G
Psychol Med. 2024; :1-10.
PMID: 39399920
PMC: 11578902.
DOI: 10.1017/S0033291724002435.
Long COVID symptoms and demographic associations: A retrospective case series study using healthcare application data.
Sunkersing D, Goodfellow H, Mu Y, Ramasawmy M, Murali M, Adams L
JRSM Open. 2024; 15(7):20542704241274292.
PMID: 39228407
PMC: 11367609.
DOI: 10.1177/20542704241274292.
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.
Griffin D
Open Forum Infect Dis. 2024; 11(9):ofae462.
PMID: 39220656
PMC: 11363684.
DOI: 10.1093/ofid/ofae462.
Psychological burden associated with incident persistent symptoms and their evolution during the COVID-19 pandemic: a prospective population-based study.
Pignon B, Matta J, Wiernik E, Toussaint A, Loewe B, Robineau O
BMJ Ment Health. 2024; 27(1).
PMID: 38490690
PMC: 11021747.
DOI: 10.1136/bmjment-2023-300907.
A longitudinal prospective cohort study of health-related quality of life assessment in outpatient adults with post-COVID-19 conditions.
Mercier K, Piche J, Rioux-Perreault C, Lemaire-Paquette S, Piche A
J Assoc Med Microbiol Infect Dis Can. 2024; 8(4):309-318.
PMID: 38250617
PMC: 10797766.
DOI: 10.3138/jammi-2023-0010.
Long COVID-associated symptoms prevalent in both SARS-CoV-2 positive and negative individuals: A prospective follow-up study.
Kantele A, Paajanen J, Pietila J, Vapalahti O, Pakkanen S, Laaveri T
New Microbes New Infect. 2024; 56:101209.
PMID: 38174103
PMC: 10761764.
DOI: 10.1016/j.nmni.2023.101209.
Complex association between post-COVID-19 condition and anxiety and depression symptoms.
Tebeka S, Carcaillon-Bentata L, Decio V, Alleaume C, Beltzer N, Gallay A
Eur Psychiatry. 2023; 67(1):e1.
PMID: 38088068
PMC: 10964277.
DOI: 10.1192/j.eurpsy.2023.2473.
Clinical characteristics of Long COVID patients presenting to a dedicated academic post-COVID-19 clinic in Central Texas.
Aziz R, Siles N, Kelley M, Wylie D, Melamed E, Brode W
Sci Rep. 2023; 13(1):21971.
PMID: 38081885
PMC: 10713530.
DOI: 10.1038/s41598-023-48502-w.
Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study.
Battaglini D, White N, Premraj L, Citarella B, Merson L, Robba C
J Neurol. 2023; 271(1):79-86.
PMID: 38055020
PMC: 10769963.
DOI: 10.1007/s00415-023-12133-y.
Haematological sequelae in the post-acute phase of symptomatic SARS-CoV-2 infection.
Bergamaschi G, Barteselli C, Calabretta F, Lenti M, Merli S, Rossi C
Intern Emerg Med. 2023; 19(1):125-133.
PMID: 38001354
DOI: 10.1007/s11739-023-03459-6.
Understanding caregivers' decision to vaccinate childhood cancer survivors against COVID-19.
Ilic A, Haardoerfer R, Michel G, Escoffery C, Mertens A, Marchak J
Cancer Med. 2023; 12(23):21354-21363.
PMID: 37937725
PMC: 10726781.
DOI: 10.1002/cam4.6675.
Increased number of symptoms during the acute phase of SARS-CoV-2 infection in athletes is associated with prolonged time to return to full sports performance-AWARE VIII.
Snyders C, Dyer M, Sewry N, Jordaan E, Schwellnus M
J Sport Health Sci. 2023; 13(3):280-287.
PMID: 37871797
PMC: 11116957.
DOI: 10.1016/j.jshs.2023.10.005.
Long COVID as a functional somatic symptom disorder caused by abnormally precise prior expectations during Bayesian perceptual processing: A new hypothesis and implications for pandemic response.
Joffe A, Elliott A
SAGE Open Med. 2023; 11:20503121231194400.
PMID: 37655303
PMC: 10467233.
DOI: 10.1177/20503121231194400.
Divergent adaptive immune responses define two types of long COVID.
Kervevan J, Staropoli I, Slama D, Jeger-Madiot R, Donnadieu F, Planas D
Front Immunol. 2023; 14:1221961.
PMID: 37559726
PMC: 10408302.
DOI: 10.3389/fimmu.2023.1221961.
Post-COVID-19 Syndrome 2 Years After the First Wave: The Role of Humoral Response, Vaccination and Reinfection.
Peghin M, De Martino M, Palese A, Chiappinotto S, Fonda F, Gerussi V
Open Forum Infect Dis. 2023; 10(7):ofad364.
PMID: 37520419
PMC: 10372856.
DOI: 10.1093/ofid/ofad364.